Linifanib is clinically active in patients with HCC, acute myeloid leukemia (AML), renal cell cancer, and NSCLC (Lowery et al., 2018), inhibiting cell proliferation, tumor growth, and metastases in ES cells in xenografts by suppressing PDGFRβ and c-kit activation (Ikeda et al., 2010). This evidence concerns the gene KIT and hepatocellular carcinoma.